The Impact of the Entry of Biosimilars: Evidence from Europe
Scott Morton F, Stern A, Stern S. The Impact of the Entry of Biosimilars: Evidence from Europe. Review Of Industrial Organization 2018, 53: 173-210. DOI: 10.1007/s11151-018-9630-3.Peer-Reviewed Original ResearchOngoing policy discussionsU.S. drug marketEntry of biosimilarsBiosimilar entryMarket featuresBiosimilar penetrationBiosimilar competitionEuropean marketPolicy discussionsPublic policyOwn surveyPricesMarketDrug marketShareCompetitionPolicySignificant heterogeneityEntryCountriesInstitutionsEuropeGenericsImpactHeterogeneity